Esperion Therapeutics (ESPR) Misses Q3 EPS by 18c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.16), $0.18 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $87.3 million versus the consensus estimate of $92.5 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal